AU2019262218B2 - Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade - Google Patents

Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade Download PDF

Info

Publication number
AU2019262218B2
AU2019262218B2 AU2019262218A AU2019262218A AU2019262218B2 AU 2019262218 B2 AU2019262218 B2 AU 2019262218B2 AU 2019262218 A AU2019262218 A AU 2019262218A AU 2019262218 A AU2019262218 A AU 2019262218A AU 2019262218 B2 AU2019262218 B2 AU 2019262218B2
Authority
AU
Australia
Prior art keywords
cells
cell
cish
car
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019262218A
Other languages
English (en)
Other versions
AU2019262218A1 (en
Inventor
Rafet BASAR
May DAHER
Katy REZVANI
Elizabeth SHPALL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2019262218A1 publication Critical patent/AU2019262218A1/en
Application granted granted Critical
Publication of AU2019262218B2 publication Critical patent/AU2019262218B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2019262218A 2018-05-03 2019-05-03 Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade Active AU2019262218B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862666665P 2018-05-03 2018-05-03
US62/666,665 2018-05-03
US201862666965P 2018-05-04 2018-05-04
US62/666,965 2018-05-04
PCT/US2019/030721 WO2019213610A1 (en) 2018-05-03 2019-05-03 Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade

Publications (2)

Publication Number Publication Date
AU2019262218A1 AU2019262218A1 (en) 2020-12-10
AU2019262218B2 true AU2019262218B2 (en) 2025-04-24

Family

ID=68386134

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019262218A Active AU2019262218B2 (en) 2018-05-03 2019-05-03 Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade

Country Status (13)

Country Link
US (1) US20210230548A1 (https=)
EP (1) EP3788061A4 (https=)
JP (2) JP2021522798A (https=)
KR (1) KR20210005240A (https=)
CN (1) CN112292390A (https=)
AU (1) AU2019262218B2 (https=)
BR (1) BR112020022010A2 (https=)
CA (1) CA3099342A1 (https=)
CO (1) CO2020015168A2 (https=)
MX (1) MX2020011697A (https=)
NZ (1) NZ770183A (https=)
SG (1) SG11202010763VA (https=)
WO (1) WO2019213610A1 (https=)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010539192A (ja) 2007-09-18 2010-12-16 リゴサイト ファーマスーティカルズ，インコーポレイテッド ノロウイルスに対して防御免疫応答を付与する方法
CA2841356C (en) 2011-07-11 2022-03-01 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
WO2018195339A1 (en) * 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
EP3706766A4 (en) * 2017-11-09 2021-08-18 Sangamo Therapeutics, Inc. GENETIC MODIFICATION OF THE CYTOCINE INDUCTIBLE SH2-CONTAINING PROTEIN (CISH) GENE
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
IL278723B2 (en) 2018-05-16 2024-07-01 Res Inst Nationwide Childrens Hospital Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
WO2020205359A1 (en) * 2019-03-29 2020-10-08 Board Of Regents, The University Of Texas System Methods for production of car-nk cells and use thereof
JP7629414B2 (ja) * 2019-06-04 2025-02-13 ンカルタ・インコーポレイテッド 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ
CN114555123B (zh) 2019-10-18 2024-04-02 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
KR20220091576A (ko) 2019-10-31 2022-06-30 포티 세븐, 인코포레이티드 혈액암의 항-cd47 및 항-cd20 기반 치료
US12195723B2 (en) * 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
CN115925976A (zh) * 2019-11-21 2023-04-07 博生吉医药科技(苏州)有限公司 Cd7-car-t细胞及其制备和应用
KR20220108793A (ko) * 2019-11-27 2022-08-03 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Msc 세포의 대규모 조합된 car 형질 도입 및 crispr 유전자 편집
US20220389383A1 (en) * 2019-11-27 2022-12-08 Board Of Regents, The University Of Texas System Large-scale combined car transduction and crispr gene editing of nk cells
LT4081305T (lt) 2019-12-24 2024-11-25 Carna Biosciences, Inc. Diacilglicerolio kinazę moduliuojantys junginiai
US20230060351A1 (en) * 2020-01-08 2023-03-02 Board Of Regents, The University Of Texas System A method of engineering natural killer cells to target cd70-positive tumors
WO2021202581A1 (en) * 2020-03-30 2021-10-07 WUGEN, Inc. Engineered immune cells for adoptive cell therapy
CN113913458A (zh) * 2020-07-09 2022-01-11 杭州优凯瑞医药科技有限公司 非病毒方法制备稳定高表达嵌合受体的nk细胞
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
JP2023552998A (ja) * 2020-12-03 2023-12-20 ンカルタ・インコーポレイテッド 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用
JP2023552895A (ja) 2020-12-15 2023-12-19 ユニフェルシテイト アントウェルペン Ｃｄ７０をターゲティングする細胞ベースの治療剤
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
AR124837A1 (es) 2021-02-09 2023-05-10 Millennium Pharm Inc Métodos y composiciones para congelar y descongelar células de mamíferos
CN113005151A (zh) * 2021-03-12 2021-06-22 广东药科大学 一种kdr-car-nk细胞的制备方法及其应用
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
IL307940A (en) 2021-04-26 2023-12-01 Millennium Pharm Inc Anti-ADGRE2 antibodies and their uses
WO2022242700A1 (en) * 2021-05-20 2022-11-24 Wuxi Biologics (Shanghai) Co., Ltd. Genetically modified nk cells and uses thereof
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN113599395B (zh) * 2021-09-22 2022-08-12 郑州源创吉因实业有限公司 含有nk细胞的治疗癌症的药物组合物
IL311665A (en) * 2021-10-01 2024-05-01 Univ Texas Antibody loaded immune cells and methods for use in cancer treatment
WO2023062113A1 (en) * 2021-10-15 2023-04-20 Miltenyi Biotec B.V. & Co. KG Method for the generation of genetically modified nk cells
WO2023070079A1 (en) * 2021-10-21 2023-04-27 Board Of Regents, The University Of Texas System Methods for production of therapeutic immune cells having enhanced metabolic fitness and compositions thereof
AU2022381757A1 (en) * 2021-11-04 2024-05-09 Saliogen Therapeutics, Inc. Immune cells with chimeric antigen receptors or chimeric autoantibody receptors
US20230149464A1 (en) 2021-11-18 2023-05-18 Janssen Biotech, Inc. Feeder free cell culture methods for expanding natural killer cell preparations
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
CN114774364B (zh) * 2022-04-26 2024-04-26 深圳市体内生物医药科技有限公司 一种嵌合抗原受体t细胞及其制备方法和应用
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
AR130860A1 (es) * 2022-10-25 2025-01-29 Takeda Pharmaceuticals Co Composiciones de linfocitos nk del receptor quimérico adgre2 y métodos de uso
CN120091827A (zh) * 2022-11-10 2025-06-03 昂克医疗有限公司 使用免疫调节药物的联合疗法
CN115947869B (zh) * 2022-11-28 2023-12-12 广州佰芮慷生物科技有限公司 一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途
CN115948344A (zh) * 2023-02-10 2023-04-11 上海交通大学 嵌合抗原受体nk细胞、制备方法及其用途
CN116731972A (zh) * 2023-02-10 2023-09-12 上海交通大学 嵌合抗原受体t细胞、制备方法及其用途
AU2024244976A1 (en) * 2023-03-24 2025-09-25 Board Of Regents, The University Of Texas System Engineered natural killer cells with enhanced antitumor memory responses
US20240358758A1 (en) * 2023-04-07 2024-10-31 Nkarta, Inc. Methods for treatment of autoimmune diseases
CN116769722B (zh) * 2023-07-04 2024-07-16 杭州荣谷生物科技有限公司 功能增强型car-nk细胞、其制备方法及其在免疫疗法中的应用
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025073908A1 (en) * 2023-10-05 2025-04-10 Onk Therapeutics Limited Optimised il-15 constructs
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170067021A1 (en) * 2015-07-31 2017-03-09 Regents Of The University Of Minnesota Modified cells and methods of therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9487800B2 (en) * 2010-09-08 2016-11-08 Chemotherapeutisches Forschunginstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
EP3692794A1 (en) * 2011-09-16 2020-08-12 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
ES2652666T3 (es) * 2011-12-22 2018-02-05 Mogam Biotechnology Institute Procedimiento de producción de linfocitos citolíticos naturales, linfocitos citolíticos naturales producidos de este modo y composición para el tratamiento de cánceres y enfermedades infecciosas que contienen los mismos
ES2952064T3 (es) * 2015-12-16 2023-10-26 Walter & Eliza Hall Inst Medical Res Inhibición de la proteína SH2 inducida por citocinas en células NK
ES2875747T3 (es) * 2016-01-11 2021-11-11 Univ Leland Stanford Junior Proteínas quiméricas y métodos de inmunoterapia
AU2017207936A1 (en) * 2016-01-15 2018-07-26 Etubics Corporation Methods and compositions for T-cell immunotherapy
CN109890408A (zh) * 2016-05-27 2019-06-14 埃特彼塞斯公司 新表位疫苗组合物及其使用方法
CA3041831A1 (en) * 2016-10-27 2018-05-03 Intima Bioscience, Inc. Viral methods of making genetically modified cells
WO2018195339A1 (en) * 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
WO2020205359A1 (en) * 2019-03-29 2020-10-08 Board Of Regents, The University Of Texas System Methods for production of car-nk cells and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170067021A1 (en) * 2015-07-31 2017-03-09 Regents Of The University Of Minnesota Modified cells and methods of therapy

Also Published As

Publication number Publication date
WO2019213610A1 (en) 2019-11-07
SG11202010763VA (en) 2020-11-27
US20210230548A1 (en) 2021-07-29
AU2019262218A1 (en) 2020-12-10
BR112020022010A2 (pt) 2021-01-26
CO2020015168A2 (es) 2021-09-09
NZ770183A (en) 2025-05-02
CN112292390A (zh) 2021-01-29
JP2021522798A (ja) 2021-09-02
KR20210005240A (ko) 2021-01-13
MX2020011697A (es) 2020-12-10
EP3788061A4 (en) 2022-02-23
CA3099342A1 (en) 2019-11-07
EP3788061A1 (en) 2021-03-10
JP2024045179A (ja) 2024-04-02

Similar Documents

Publication Publication Date Title
AU2019262218B2 (en) Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
US20260102335A1 (en) Immune cells expressing engineered antigen receptors
JP7672702B2 (ja) 機能および抑制性環境に対する抵抗性を増強するための免疫細胞のマルチプレックスゲノム編集
US20220389383A1 (en) Large-scale combined car transduction and crispr gene editing of nk cells
US20230045174A1 (en) Large-scale combined car transduction and crispr gene editing of msc cells
WO2022251377A1 (en) Inhibitory chimeric antigen receptor prevents on-target off-tumor effects of adoptive cell therapy
AU2020392222A1 (en) Large-scale combined CAR transduction and CRISPR gene editing of B cells
US20220401479A1 (en) Large-scale combined car transduction and crispr gene editing of t cells
EA048895B1 (ru) Мультиплексное редактирование генома иммунных клеток для повышения функциональности и устойчивости к подавляющей среде

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)